Clinical Investigation of the Next-Generation Intraocular Lenses

NCT ID: NCT03372434

Last Updated: 2025-06-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 225 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-01-16
• Study Completion Date: 2018-10-30

Brief Summary

This study is a 6-month, prospective, multicenter, subject/evaluator-masked, bilateral, randomized clinical investigation of the TECNIS Next-Generation Model ZFR00 and Model ZYR00 IOLs versus the TECNIS Multifocal Model ZLB00 control IOL.

The study will be conducted at up to 14 sites in the U.S.A and will enroll up to 260 subjects to achieve approximately 220 randomized and bilaterally-implanted subjects, resulting in approximately 195 evaluable subjects (65 in each test group and 65 in the control group) at 1 and 6 months. Subjects are to be implanted with the same IOL in both eyes, the ZFR00 IOL, the ZYR00 IOL or the ZLB00 control IOL. The eye implanted first will be considered the primary study eye.

Conditions

Cataract

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Investigational Lens Device #1

Investigational Intraocular Lens Device #1: Model ZFR00

Group Type: EXPERIMENTAL

Investigational Intraocular Lens Device #1: Model ZFR00

Intervention Type: DEVICE

IOL replaces the natural lens removed during cataract surgery.

Investigational Lens Device #2

Investigational Intraocular Lens Device #1: Model ZYR00

Group Type: EXPERIMENTAL

Investigational Intraocular Lens Device #1: Model ZYR00

Intervention Type: DEVICE

IOL replaces the natural lens removed during cataract surgery.

Control Device

Control TECNIS Multifocal Intraocular Lens Model ZLB00

Group Type: ACTIVE_COMPARATOR

TECNIS Multifocal Intraocular Lens: Model ZLB00

Intervention Type: DEVICE

IOL replaces the natural lens removed during cataract surgery.

Interventions

Investigational Intraocular Lens Device #1: Model ZFR00

IOL replaces the natural lens removed during cataract surgery.

Intervention Type: DEVICE

Investigational Intraocular Lens Device #1: Model ZYR00

IOL replaces the natural lens removed during cataract surgery.

Intervention Type: DEVICE

TECNIS Multifocal Intraocular Lens: Model ZLB00

IOL replaces the natural lens removed during cataract surgery.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Minimum 22 years of age
• Bilateral cataracts for which posterior chamber IOL implantation has been planned
• Preoperative best corrected distance visual acuity (BCDVA) of 20/40 Snellen or worse with a glare source or 20/40 Snellen or worse without a glare source
• Potential for postoperative BCDVA of 20/30 Snellen or better
• Corneal astigmatism:

• Normal corneal topography
• Preoperative corneal astigmatism of 1.00 D or less in both eyes
• Clear intraocular media other than cataract in each eye
• Availability, willingness and sufficient cognitive awareness to comply with examination procedures
• Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries
• Ability to understand and respond to a questionnaire in English

Exclusion Criteria

• Requiring an intraocular lens power outside the available range of +14.0 D to +26.0 D
• Any clinically-significant pupil abnormalities (non-reactive, fixed pupils, or abnormally-shaped pupils)
• Irregular corneal astigmatism
• Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.)
• Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery. Note: Prophylactic peripheral iridotomies and peripheral laser retinal repairs that, in the opinion of the investigator will not confound study outcome or increase risk to the subject, are acceptable.
• Corneal abnormalities such as stromal, epithelial or endothelial dystrophies that are predicted to cause visual acuity losses to a level worse than 20/30 Snellen during the study
• Inability to achieve keratometric stability for contact lens wearers (per procedure outlined in Section 10.3)
• Recent ocular trauma or ocular surgery that is not resolved/stable or may affect visual outcomes or increase risk to the subject
• Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that are predicted to cause visual acuity losses to a level worse than 20/30 Snellen during the study
• Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects
• Use of systemic or ocular medications that may affect vision
• Prior, current, or anticipated use during the course of the 6-month study of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) that may, in the opinion of the investigator, confound the outcome or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery)
• Poorly-controlled diabetes
• Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study (e.g., immunocompromised, connective tissue disease, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.). Note: controlled ocular hypertension without glaucomatous changes (optic nerve cupping and visual field loss) is acceptable.
• Known ocular disease or pathology that, in the opinion of the investigator,

• may affect visual acuity
• may require surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, uncontrolled glaucoma, etc.)
• may be expected to require retinal laser treatment or other surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, etc.)
• Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes
• Concurrent participation or participation within 60 days prior to preoperative visit in any other clinical trial
• Desire for monovision correction

• Minimum Eligible Age: 22 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Abbott Medical Optics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Abbott Medical Optics Clinical Trials

Role: STUDY_DIRECTOR

Abbott Medical Optics

Locations

Empire Eye & Laser Center

Bakersfield, California, United States

Katzen Eye Care and Laser Center

Boynton Beach, Florida, United States

Chesapeake Eye Care & Laser Center

Annapolis, Maryland, United States

Eye Doctors of Washington

Chevy Chase, Maryland, United States

Scott & Christie and Associates, PC

Cranberry Township, Pennsylvania, United States

Carolina EyeCare Physicians, LLC

Mt. Pleasant, South Carolina, United States

Loden Vision Centers

Goodlettsville, Tennessee, United States

Eye Specialty Group

Memphis, Tennessee, United States

Texas Eye and Laser Center

Hurst, Texas, United States

Lehmann Eye Center

Nacogdoches, Texas, United States

Focal Point Vision

San Antonio, Texas, United States

Clarus Eye Centre

Lacey, Washington, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

SUR-CAT-652-1001

Identifier Type: -

Identifier Source: org_study_id